Karyopharm Therapeutics Inc. — FY2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. The filing also reports unaudited fourth-quarter results. This is an annual report, not a standalone Q4 filing. The company is a clinical-stage oncology drug developer; it had no revenue from drug sales.
Business context and reporting period
Karyopharm’s lead candidate, selinexor, is an oral XPO1 inhibitor being studied in blood cancers and solid tumors. Other clinical-stage programs include eltanexor and KPT-9274; verdinexor is licensed for companion-animal cancer and certain non-oncology development. Reported 2018 revenue came from licensing and other sources, not product sales.
Financial performance and position
| Metric | FY2018 | FY2017 |
|---|---|---|
| License and other revenue | $30.3 million | $1.6 million |
| Research and development expense | $161.4 million | $107.3 million |
| General and administrative expense | $48.8 million | $24.9 million |
| Operating loss | $179.9 million | $130.5 million |
| Net loss | $178.4 million | $129.0 million |
| Net loss per share, basic and diluted | $3.14 | $2.81 |
| Net cash used in operating activities | $159.1 million | $73.7 million |
Revenue was uneven and largely transaction-driven: 2018 included $10.0 million recognized from the Biogen asset sale and $19.7 million from the Ono license. The company reported no gross margin or product-sales margin; operating margins are not meaningfully comparable because revenue is primarily licensing-related and expenses substantially exceeded revenue.
| Q4 2018 unaudited metric | Value |
|---|---|
| License and other revenue | $0.2 million |
| Operating expenses | $57.7 million |
| Operating loss | $57.5 million |
| Net loss | $58.2 million |
| Net loss per share | $0.96 |
At December 31, 2018, cash, cash equivalents and investments totaled approximately $330.2 million; working capital was $287.7 million and total assets were $341.2 million. The company stated that available cash and investments were expected to fund current plans for at least 12 months from issuance of the financial statements. No revenue or cash-flow margin was reported as a useful operating measure.
In October 2018, Karyopharm issued $172.5 million principal amount of 3.00% convertible senior notes due 2025, receiving $166.9 million net proceeds. The notes’ balance-sheet carrying amount was $102.7 million after accounting for the conversion feature and issuance costs; the stated effective interest rate on the liability component was 11.85%. The company’s accumulated deficit was $673.7 million.
Material changes versus the prior comparable period
- Revenue rose to $30.3 million from $1.6 million, principally from Biogen and Ono transactions; it remains non-product revenue.
- R&D expense increased $54.1 million, mainly from selinexor clinical trials, NDA-related consulting and professional costs, and higher personnel expenses.
- G&A expense increased $23.9 million, including commercial-readiness, hiring, consulting and occupancy costs.
- Net loss widened by $49.4 million, while operating cash use increased by $85.4 million.
- Cash and investments increased materially, supported by $145.7 million net proceeds from a May 2018 common-stock offering and $166.9 million net proceeds from the notes offering. Shares outstanding increased from 49.5 million to 60.8 million by year-end.
Outlook, commentary, risks and unusual items
- Selinexor regulatory risk: The FDA accepted the multiple-myeloma NDA for priority review, with an April 6, 2019 action date. However, the advisory committee voted 8–5 to recommend delaying approval until randomized Phase 3 BOSTON results are available. FDA concerns included the single-arm evidence, toxicity and dose optimization. The committee recommendation was advisory, not a final FDA decision.
- Clinical and safety risks: BOSTON enrollment was completed in January 2019; top-line results were expected no earlier than late 2019 or 2020. The company reported frequent nausea, fatigue, anorexia and thrombocytopenia in selinexor studies. In STORM, approximately 78% of patients had a dose modification and 26.8% discontinued treatment because of adverse events.
- Other studies: SADAL reported a 29.6% response rate in relapsed/refractory DLBCL; the company planned to seek accelerated approval, subject to FDA discussions. SEAL Phase 2 showed median progression-free survival of 5.5 months versus 2.7 months for placebo; Phase 3 data were expected in 2020.
- Spending plans: Management expected R&D expense to decrease in 2019 as it moderated development spending while prioritizing selinexor and regulatory submissions. G&A was expected to rise to support commercial activities, but the company said it would reassess spending following FDA discussions. A U.S. launch as early as the first half of 2019 was conditional on approval.
- Funding and financing: The company remained loss-making, expected significant future expenses and stated that additional financing might be needed. It warned that further equity issuance could dilute shareholders and that debt service, conversion or repurchase obligations could pressure liquidity. A $75 million at-the-market facility had not been used by year-end.
- Other key risks: Clinical-trial outcomes and regulatory decisions are uncertain; competitors, reimbursement and pricing pressure may limit commercialization. The company relies on third parties for manufacturing and clinical work and had no redundant supply arrangements. There were no material legal proceedings reported.
Important facts for investors to verify
- Subsequent FDA action on the selinexor multiple-myeloma NDA, including how the agency responds to the advisory committee vote and whether BOSTON results are required.
- Timing and results of BOSTON, SADAL-related regulatory submissions, and the SEAL Phase 3 study.
- Actual cash burn and runway against management’s stated minimum 12-month funding outlook, particularly if approval is delayed and launch spending changes.
- Convertible-note terms and liquidity exposure: $172.5 million principal, 3.00% coupon, 2025 maturity, conversion price of approximately $15.85, and potential cash settlement or repurchase requirements.
- How much of future reported revenue depends on additional licensing milestones or royalties rather than product sales, and whether licensing obligations are fulfilled as expected.
- Selinexor tolerability, dose optimization, discontinuation rates and the implications of reported adverse events for labeling, uptake and commercial viability.